SLL Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Terminated
  • Chronic Lymphocytic Leukemia
  • +3 more
  • TP-0903
  • TP-0903 and ibrutinib combination therapy
  • Phoenix, Arizona
  • +5 more
2022-04-04
Apr 4, 2022
T
Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
2022-03-22
Mar 22, 2022
M
Withdrawn
  • CLL
  • +4 more
  • Treatment Free Observation
  • Basking Ridge, New Jersey
  • +8 more
2022-03-04
Mar 4, 2022
G
Recruiting
  • CLL
  • +7 more
    • Dresden, Sachsen, Germany
      BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
    2021-12-16
    Dec 16, 2021
    V
    Withdrawn
    • Chronic Lymphocytic Leukemia
    • +8 more
    • Dose combination 1-1
    • +5 more
    • (no location specified)
    2021-11-01
    Nov 1, 2021
    C
    Recruiting
    • Lymphocytic Leukemia, Chronic
    • SLL
    • Durham, North Carolina
    • +1 more
    2021-09-16
    Sep 16, 2021
    G
    Completed
    • NHL
    • +17 more
    • veltuzumab
    • Savannah, Georgia
    • +4 more
    2021-08-12
    Aug 12, 2021
    U
    Completed
    • Lymphoma
    • +3 more
    • Tucson, Arizona
      The University of Arizona Cancer Center
    2019-12-16
    Dec 16, 2019
    Å
    Terminated
    • Chronic Lymphocytic Leukemia
    • +3 more
    • La Jolla, California
      Moores Cancer Center, UCSD
    2016-07-11
    Jul 11, 2016